At Nanostics, we predict disease risk using the ClarityDX platform, an advanced technology that combines artificial intelligence with proprietary and/or established biomarker data from minimally invasive biofluid samples, such as blood or urine, together with relevant clinical information to deliver rapid, accurate, and clinically meaningful results.
The ClarityDX platform is designed to transform disease screening by enabling easy-to-use, minimally invasive predictive tests that support better decision-making and improved patient outcomes.